-The Hindu Business Line Come November, the Jan Aushadhi initiative completes nine years. But despite its recent achievements, there's more work to be done. PT Jyothi Datta writes Earlier this year, Chemicals and Fertilizers Minister Ananth Kumar vowed to end the “medicine mafia” in the country by opening many more Jan Aushadhi kendras, stores that sell generic medicines at affordable prices. Kumar was echoing the mission outlined by Finance Minister Arun Jaitley...

-The Times of India and other agencies WASHINGTON: United States President Donald Trump has promised to bring the cost of prescription drugs in the country "way down" and let other countries pay more for these medicines. If effected, Trump's new policy on prescription drugs, dicussed with his cabinet at the White House on Monday, could have grave implications for India. The US has long had a grouse with India over its patent...

-PTI The government has formed a committee in its bid to make drugs more affordable in the country, Parliament was informed on Tuesday. “Government has constituted a committee of joint secretaries for ensuring enhanced affordability, availability and accessibility of drugs for the citizens,” Minister of State for Chemicals and Fertilisers Mansukh L. Mandaviya said in a written reply to Lok Sabha. Elaborating on the terms of reference of the committee, the minister said...

-The Hindu India must counter Japan’s U.S.-style pressure at the RCEP talks and ensure affordable generic medicines Leaked texts are like leaked gases — you may never find the one responsible for it, but the mayhem caused by its release is hard to contain. Unsurprisingly, all public discussions on the Regional Comprehensive Economic Partnership (RCEP) are centred around leaked documents. As India negotiates the RCEP — a free trade agreement that looks...

-The Telegraph New Delhi: India's drug pricing rules allow companies to inflate the maximum retail prices of medicines, including life-saving drugs, costing patients thousands of additional rupees while offering slices of the profits to stockists, chemists, and hospitals. Quotations received by hospitals from drug companies' representatives offering discounts on maximum retail prices (MRPs) of medicines provide what some doctors and patients' rights advocates say is fresh evidence for excessive profiteering in India's...